Quinazoline derivatives: synthesis and bioactivities

Chemistry Central Journal

Dan Wang¹  Feng Gao¹ 

[1] Department of Chinese Traditional Herbal, Agronomy College, Sichuan Agricultural University, No. 211, Huiming Road, Wenjiang Region, Chengdu, 611130, P. R. China

关键词: Bioactivity;    Synthesis;    Quinazoline derivative;   

Others  :  787898
DOI  :  10.1186/1752-153X-7-95

 received in 2013-02-22, accepted in 2013-04-26,  发布年份 2013

【 摘 要 】

Owing to the significant biological activities, quinazoline derivatives have drawn more and more attention in the synthesis and bioactivities research. This review summarizes the recent advances in the synthesis and biological activities investigations of quinazoline derivatives. According to the main method the authors adopted in their research design, those synthetic methods were divided into five main classifications, including Aza-reaction, Microwave-assisted reaction, Metal-mediated reaction, Ultrasound-promoted reaction and Phase-transfer catalysis reaction. The biological activities of the synthesized quinazoline derivatives also are discussed.

【 授权许可】

   
2013 Wang and Gao; licensee Chemistry Central Ltd.

【 图 表 】

Scheme 1

Scheme 2

Scheme 3

Scheme 4

Scheme 5

Scheme 6

Scheme 7

Scheme 8

Scheme 9

Scheme 10

Scheme 11

Scheme 12

Scheme 13

Scheme 14

Figure 1.

Scheme 15

Scheme 16

Scheme 17

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Chandregowda V, Kush AK, Chandrasekara Reddy G: Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives. Eur J Med Chem 2009, 44:3046-3055.
• [2]Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI: Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg Med Chem 2006, 14:8608-8621.
• [3]Vasdev N, Dorff PN, Gibbs AR, Nandanan E, Reid LM, Neil JPO’, VanBrocklin HF: Synthesis of 6-acrylamido-4-(2-[18F] fluoroanilino) quinazoline: A prospective irreversible EGFR binding probe. J Lablelled Compd Rad 2005, 48:109-115.
• [4]Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749-5754.
• [5]Alagarsamy V, Solomon VR, Dhanabal K: Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3H -quinazolin-4-one as analgesic, anti-inflammatory agents. Bioorg Med Chem 2007, 15:235-241.
• [6]Baba A, Kawamura N, Makino H, Ohta Y, Taketomi S, Sohda T: Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect1. J Med Chem 1996, 39:5176-5182.
• [7]Rohini R, Muralidhar Reddy P, Shanker K, Hu A, Ravinder V: Antimicrobial study of newly synthesized 6-substituted indolo[1,2-c]quinazolines. Eur J Med Chem 2010, 45:1200-1205.
• [8]Antipenko L, Karpenko A, Kovalenko S, Katsev A, Komarovska-Porokhnyavets E, Novikov V, Chekotilo A: Synthesis of new 2-thio-[1,2,4]triazolo[1,5-c]quinazoline derivatives and its antimicrobial activity. Chem Pharm Bull 2009, 57:580-585.
• [9]Jatav V, Kashaw S, Mishra P: Synthesis and antimicrobial activity of some new 3–[5-(4-substituted)phenyl-1,3,4-oxadiazole-2yl]-2-styrylquinazoline-4(3H)-ones. Med Chem Res 2008, 17:205-211.
• [10]Aly AA: Synthesis of novel quinazoline derivatives as antimicrobial agents. Chin J Chem 2003, 21:339-346.
• [11]Li H, Huang R, Qiu D, Yang Z, Liu X, Ma J, Ma Z: Synthesis and bioactivity of 4-quinazoline oxime ethers. Prog Nat Sci 1998, 8:359-365.
• [12]Chandrika PM, Yakaiah T, Narsaiah B, Sridhar V, Venugopal G, Rao JV, Kumar KP, Murthy USN, Rao ARR: Synthesis leading to novel 2,4,6-trisubstituted quinazoline derivatives, their antibacterial and cytotoxic activity against THP-1, HL-60 and A375 cell lines. Indian J Chem 2009, 48B:840-847.
• [13]Paneersalvam P, Raj T, Ishar PS M, Singh B, Sharma V, Rather BA: Anticonvulsant activity of Schiff bases of 3-amino-6,8-dibromo-2-phenyl-quinazolin-4(3H)-ones. Indian J Pharm Sci 2010, 72:375-378.
• [14]Nandy P, Vishalakshi MT, Bhat AR: Synthesis and antitubercular activity of Mannich bases of 2-methyl-3H-quinazolin-4-ones. Indian J Heterocycl Chem 2006, 15:293-294.
• [15]Saravanan G, Alagarsamy V, Prakash CR: Synthesis and evaluation of antioxidant activities of novel quinazoline derivatives. Int J Pharm Pharm Sci 2010, 2:83-86.
• [16]Lakhan R, Singh OP, Singh-J RL: Studies on 4 (3H)-quinazolinone derivatives as anti-malarials. J Indian Chem Soc 1987, 64:316-318.
• [17]Hess HJ, Cronin TH, Scriabine A: Antihypertensive 2-amino-4(3H)-quinazolinones. J Med Chem 1968, 11:130-136.
• [18]Sasmal S, Balaji G, Kanna Reddy HR, Balasubrahmanyam D, Srinivas G, Kyasa S, Sasmal PK, Khanna I, Talwar R, Suresh J, Jadhav VP, Muzeeb S, Shashikumar D, Harinder Reddy K, Sebastian VJ, Frimurer TM, Rist Ø, Elster L, Högberg T: Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists. Bioorg Med Chem Lett 2012, 22:3157-3162.
• [19]Alvarado M, Barceló M, Carro L, Masaguer CF, Raviña E: Synthesis and biological evaluation of new quinazoline and cinnoline derivatives as potential atypical antipsychotics. Chem Biodivers 2006, 3:106-117.
• [20]Malamas MS, Millen J: Quinazolineacetic acids and related analogs as aldose reductase inhibitors. J Med Chem 1991, 34:1492-1503.
• [21]Povarov LS: α, β-Unsaturated ethers and their analogues in reactions of diene synthesis. Russ Chem Rev 1967, 36:656-669.
• [22]Reymond S, Cossy J: Copper-catalyzed Diels-alder reactions. Chem Rev 2008, 108:5359-5406.
• [23]Chen X, Wei H, Yin L, Li X: A convenient synthesis of quinazoline derivatives via cascade imimo-Diels-Alder and oxidation reaction. Chin Chem Lett 2010, 21:782-786.
• [24]Molina P, Vilaplana MJ: Iminophosphoranes: useful building blocks for the preparation of nitrogen-containing heterocycles. Synthesis 1994, 1994:1197-1218.
• [25]He P, Nie YB, Wu J, Ding MW: Unexpected synthesis of indolo[1,2-c]quinazolines by a sequential ugi 4CC-Staudinger-aza-Wittig-nucleophilic addition reaction. Org Biomol Chem 2011, 9:1429-1436.
• [26]Ding MW, Yang SJ, Chen YF: Synthesis and fungicidal activities of 2-alkoxy-3H-quinazolin-4-ones. Chin J Org Chem 2004, 24:923-026.
• [27]Barthelemy S, Schneider S, Bannwarth W: Parallel fluorous biphasic synthesis of 3H-quinazolin-4-ones by an Aza-Wittig reaction employing perfluoroalkyl-tagged triphenylphosphine. Tetrahedron Lett 2002, 43:807-810.
• [28]Mavandadi F, Lidstrom P: Microwave- assisted chemistry in drug discovery. Curr Top Med Chem 2004, 4:773-792.
• [29]Gedye R, Smith F, Westaway K, Ali H, Baldisera L: The use of microwave ovens for rapid organic synthesis. Tetrahedron Lett 1986, 27:279-282.
• [30]Liu YP, Yin DC, Chen HT, Sun BG: Rapid synthesis of flavor compound 4-ethyloctanoic acid under microwave irradiation. Int J Mol Sci 2010, 11:4165-4174.
• [31]Cleophax J, Liagre M, Loupy A, Petit A: Application of focused microwaves to the scale-up of solvent-free organic reactions. Org Process Res Dev 2000, 4:498-504.
• [32]Luo H, Hu D, Wu J, He M, Jin L, Yang S, Song B: Rapid synthesis and antiviral activity of (quinazolin-4-ylamino)methyl-phosphonates through microwave irradiation. Int J Mol Sci 2012, 13:6730-6746.
• [33]Tu S, Li C, Li G, Cao L, Shao Q, Zhou D, Jiang B, Zhou J, Xia M: Microwave-assisted combinatorial synthesis of polysubstituent imidazo[1,2-a]quinoline, pyrimido[1,2-a]quinoline and quinolino[1,2-a]quinazoline derivatives. J Comb Chem 2007, 9:1144-1148.
• [34]Kidwai M, Saxena S, Khalilur Rahman Khan M, Thukral SS: Synthesis of 4-aryl-7,7-dimethyl-1,2,3,4,5,6,7,8-octahydroquinazoline-2-one/thione-5-one derivatives and evaluation as antibacterials. Eur J Med Chem 2005, 40:816-819.
• [35]Hazarkhani H, Karimi B: A facile synthesis of new 3-(2-benzimidazolyl)-2-alkyl-4-(3H)-quinazolinones under microwave irradiation. Tetrahedron 2003, 59:4757-4760.
• [36]Qiu G, He Y, Wu J: Preparation of quinazolino[3,2-a]quinazolines via a palladium-catalyzed three-component reaction of carbodiimide, isocyanide, and amine. Chem Commun 2012, 48:3836-3838.
• [37]McGowan MA, McAvoy CZ, Buchwald SL: Palladium-catalyzed N-monoarylation of amidines and a one-pot synthesis of quinazoline derivatives. Org Lett 2012, 14:3800-3803.
• [38]Shi DQ, Rong SF, Dou GL, Wang MM: One-pot synthesis of imidazo[1,2-c]quinazoline derivatives from nitro-componds reduced by Zinc. J Heterocyclic Chem 2009, 46:971-974.
• [39]McMurry JE, Fleming MP: Prepared from o-anisaldehyde. J Am Chem Soc 1974, 96:4708-4709.
• [40]Shi DQ, Shi CL, Wang JX, Rong LC, Zhuang QY, Wang XS: An efficient synthesis of quinazoline derivatives with the aid of low-valent Titanium reagent. J Heterocyclic Chem 2005, 42:173-183.
• [41]Sang P, Xie YJ, Zou JW, Zhang YH: Copper-catalyzed sequential Ullmann N-arylation and aerobic oxidative C-H amination: a convenient route to indolo[1,2-c]quinazoline derivatives. Org Lett 2012, 14:3894-3897.
• [42]Jiang M, Li J, Wang F, Zhao YC, Zhao F, Dong XC, Zhao WL: A facile Copper-catalyzed one-pot domino synthesis of 5,12-dihydroindolo[2,1-b]quinazolines. Org Lett 2012, 14:1420-1423.
• [43]Kundu NG, Gopeswar C: Copper-catalysed heteroannulation with alkynes: a general and highly regio- and stereoselective method for the systhesis of (E)-2-(2-arylvinyl) quinazolines. Tetrahedron 2001, 57:6833-6842.
• [44]Bischler A, Barad D: Zur Kenntniss der pheomiazinderivte. Berichte 1892, 25:3080-3097.
• [45]Schofield K, Swain T, Theobald RS: The preparation of some α ω-di-quinazolinylalkanes. J Chem Soc 1952, 1924-1926.
• [46]Ferrini S, Ponticelli F, Taddei M: Convenient synthetic approach to 2,4-disubstituted quinazolines. Org Lett 2007, 9:69-72.
• [47]Schofield K: Miscellaneous quinazoline derivatives. J Chem Soc 1954, 4034-4035.
• [48]Zhang L, Gao Z, Peng C, Bin ZY, Zhao D, Wu J, Xu Q, Li JX: Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives. Mol Divers 2012, 16:579-590.
• [49]Dehmlow EV, Dehmlow SS: Phase Transfer Catalysis. New York: VCH Publisher; 1993:12.
• [50]Stark CM, Liotta C, Halpern M: Phase Transfer Catalysis, Fundamentals, Application and Industrial Perspectives.. New York: Chapman & Hall; 1994:25.
• [51]Sasson Y, Neumann R: Handbook of Phase Transfer Catalysis. New York: Chapman & Hall; 1997:126.
• [52]Khalil AK: Phase-transfer catalyzed alkylation and cycloalkylation of 2-mercaptoquinazolin-4(3H)-one. Phosphorus Sulfur 2005, 180:2533-2541.
• [53]Ma Y, Liu F, Yan K, Song BA, Yang S, Hu DY, Jin LH, Xue W: Synthesis and antifungal bioactivity of 6-bromo-4-alkylthio-quinazoline derivatives. Chin J Org Chem 2008, 28:1268-1272.
• [54]Rohini R, Shanker K, Reddy PM, Ho YP, Ravinder V: Mono and bis-6-arylbenzimidazo[1,2-c]quinazolines: A new class of antimicrobial agents. Eur J Med Chem 2009, 44:3330-3339.
• [55]Pandey SK, Singh A, Singh A, Nizamuddin : Antimicrobial studies of some novel quinazolinones fused with [1,2,4]-triazole, [1,2,4]-triazine and [1,2,4,5]-tetrazine rings. Eur J Med Chem 2009, 44:1188-1197.
• [56]Zhang G, Liang YQ, Zhang RL, Zhang WH, Zhao JS, Guo ZA: Synthesis and Crystal Structure of a New Quinazolinone compound 2,3-dihydro-2-(2-hydroxyphenyl)-3-phenyl-quinazolin-4(1H)-one. Chinese J Struct Chem 2005, 24:783-788.
• [57]Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Nagase Y, Iida I, Yamaguchi J, Semple G, Tran TA, Sekiguchi Y: Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem 2006, 14:3307-3319.
• [58]Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Semple G, Tran TA, Kramer B, Hsu D, Casper M, Thomsen B, Sekiguchi Y: Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett 2005, 15:3853-3856.
• [59]Chaki S, Funakoshi T, Hirota-Okuno S, Nishiguchi M, Shimazaki T, Iijima M, Grottick AJ, Kanuma K, Omodera K, Sekiguchi Y, Okuyama S, Tran TA, Semple G, Thomsen W: Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: Nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 2005, 313:831-839.
• [60]Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265:1093-1095.
• [61]Rewcastle GW, Denny WA, Bridges AJ, Zhou H, Cody DR, McMichael A, Fry DW: Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenyl-methyl)amino]- and 4-(phenylamino)quinazolines as potent ad-enosine-5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995, 38:3482-3487.
• [62]Barker AJ: Quinazoline derivatives. Eur Patent Appl 1993, 0566226A1.
• [63]Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR: Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994, 48:659-666.
• [64]Bridges AJ, Zhou H, Cody DR, Rewcastle GW, Mc-Michael A, Showalter HDH, Fry DW, Kraker AJ, Denny WA: Tyrosine kinase inhibitors. 8. An unusually steep structure activity relationship for analogues of 4-(3-bromo-anilino)-6,7-dimethoxyqinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996, 39:267-276.
• [65]Bridjes AJ: Chemical inhibitors of protein kinases. Chem Rev 2001, 101:2541-2571.
• [66]Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD: Tyrosine kinase inhibitors. 19. 6-alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. J Med Chem 2006, 49:1475-1485.
• [67]Hickey K, Grehan D, Reid IM: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen pre-dicts response of esophageal squamous cell carcinoma to chemora-diotherapy. Cancer 1994, 74:1693-1698.
• [68]Lü S, Zheng W, Ji L, Luo Q, Hao X, Li X, Wang F: Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. Eur J Med Chem 2013, 61:84-89.
• [69]Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L, Wang Y: Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett 2012, 22:6301-6305.
• [70]Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM: Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Nat Acad Sci USA 1998, 95:12022-12027.
• [71]Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Schowalter HDH, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ: Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999, 42:1803-1815.
• [72]Nandi AK, Chaudhri S, Mazumdah SK, Gosh S: Effect of chlorine substitution on the structure and activity of 4-phenylthiosemicarbazide: crystal and molecular structure of 4-(4-chlorophenyl) thiosemicarbazide. J Chem Soc Perkin Trans 1984, 2:1729-1733.
• [73]Ali MA, Chowdhary DA, Naziruddin M: Four- and five-coordinatecopper(II) complexes containing mixed ligands. Polyhedron 1984, 3:595-598.
• [74]Scovill JP, Klayman DL, Franchino CF: 2-Acetylpyridine thiosemicarbazones. 4. Complexes with transition metals as antimalarial and antileukemic agents. J Med Chem 1982, 25:1261-1264.
• [75]He JB, Wang XG, Zhao XQ, Liang YJ, He HW, Fu LW: Synthesis and antitumor activity of novel quinazoline derivatives containing thiosemicarbazide moiety. Eur J Med Chem 2012, 54:925-930.
• [76]Bonner JC, Lindroos PM, Rice AB, Moomaw CR, Morgan DL: Induction of PDGF receptor-alpha in rat myofi-broblasts during pulmonary fibrogenesis in vivo. Am J Physiol 1998, 274:72-80.
• [77]Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250.
• [78]Gesualdo L, Pinzani M, Floriano JJ, Hassan MO, Nagy NU, Schena FP, Emancipator SN, Abboud HE: Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab Invest 1991, 65:160-167.
• [79]Heldin CH, Westermark B: Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990, 1:555-566.
• [80]Iida H, Seifert R, Alpers CE, Gronwald RG, Phillips PE, Pritzl P, Gordon K, Gown AM, Ross R, Bowen-Pope DF: Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci USA 1991, 88:6560-6564.
• [81]Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992, 175:1413-1416.
• [82]Rice AB, Moomaw CR, Morgan DL, Bonner JC: Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999, 155:213-221.
• [83]Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Malden LT, Masuko H, Sato H: Localization of PDGF-B protein in macrophages in all phases of atherogen-esis. Science 1990, 248:1009-1012.
• [84]Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D: Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988, 82:1134-1143.
• [85]Wong L, Yamasaki G, Johnson RJ, Friedman SL: Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994, 94:1563-1569.
• [86]Yagi M, Kato S, Kobayashi Y, Kobayashi N, Iinuma N, Nakamura K, Kubo K, Ohyama S, Murooka H, Shimizu T, Nishitoba T, Osawa T, Nagano N: Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor auto-phosphorylation in the rat with mesangial proliferative glom-erulonephritis. Gen Pharmacol 1998, 31:765-773.
• [87]Matsuno K, Ichimura M, Nakajima T, Tahara K, Fujiwara S, Kase H, Ushiki J, Giese NA, Pandey A, Scarborough RM, Lokker NA, Yu JC, Irie J, Tsukuda E, Ide S, Oda S, Nomoto Y: Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. J Med Chem 2002, 45:3057-3066.
• [88]Rewcastle GW, Palmer BD, Bridges AJ, Showalter HDH, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA: Tyrosine kinase inhibitors. 9. synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1996, 39:918-928.
• [89]Jantova S, Ovadekova R, Letasiova S, Spirkova K, Stankovsky S: Antimicrobial activity of some substituted triazoloquinazolines. Folia Microbiol 2005, 50:90-94.
• [90]Nasr MN, Gineinah MM, El-Bendary ER: Synthesis and in vitro antibacterial evaluation of novel imidazo[2′,1′:5,1]-1,2,4-triazolo[4,3-c]-quinazoline derivatives of 5-thioxo-1, 2, 4-triazole, 4-oxothiazolidine, and their open-chain counterparts. Arch Pharm 2003, 336:560-566.
• [91]Ibrahim SS, Abdel-Halim AM, Gabr Y, El-Edfawy S, Abdel-Rahman RM: Synthesis and biological evaluation of some new fused quinazoline derivatives. J Chem Res 1997, 5:1041-1063.
• [92]El-Sayed R, Wasfy AF: Synthesis of heterocycle having double characters as antimicrobial and surface active agents. J Chin Chem Soc 2005, 52:129-135.
• [93]El-Sayed R, Wasfy AAF, Aly AA: Synthesis of novel heterocycles with antimicrobial and surface activity. J Heterocycl Chem 2005, 42:125-130.
• [94]Bhalla M, Srivastava VK, Bhalla TN, Shanker K: Anti-inflammatory and analgesic activity of indolyl quinazolones and their congeners. Arzneimittelforschung 1993, 43:595-600.
• [95]Hitkari A, Saxena M, Verma AK, Gupta M, Shankar MP: Substituted quinazolinones and their anti-inflammatory activity. Bull Chim Farm 1995, 134:609-615.
• [96]Alagarsamy V, Solomon VR, Vanikavitha G, Paluchamy V, Ravichandran M, Sujin AA, Thanga-thirupathy A, Amuthalakshmi S, Revathi R: Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-phenyl-3-substituted quinazolin-4(3H)-ones. Biol Pharm Bull 2002, 25:1432-1435.
• [97]Alagarsamy V, Murugananthan G, Venkateshperumal R: Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-methyl-3-substituted quinazolin-4-(3H)-ones. Biol Pharm Bull 2003, 26:1711-1714.
• [98]Alagarsamy V, Rajesh R, Meena R, Vijaykumar S, Ramseshu KV, Anandakumar TD: Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-methylthio-3-substituted quinazolin-4-(3H)-ones. Biol Pharm Bull 2004, 27:652-656.
• [99]Alagarsamy V, Muthukumar V, Pavalarani N, Vasan-thanathan P, Revathi R: Synthesis, analgesic and anti-inflammatory activities of some novel 2,3-disubstituted quinazolin-4(3H)-ones. Biol Pharm Bull 2003, 26:557-559.
• [100]Bhati SK, Kumar A: Synthesis of new substituted azetidinoyl and thiazolidinoyl-1,3,4-thiadiazino(6,5-b)indoles as promising anti-inflammatory agents. J Med Chem 2008, 43:2323-2330.
• [101]Sonar VN, Yazadan SK, Sreenivasulu N: Synthesis of oxadiazolylindole derivatives and their anti-inflammatory activity. Indian J Heterocycl Chem 2001, 19:299-302.
• [102]Wincent E, Shirani H, Bergman J, Rannug U, Janosik T: Synthesis and biological evaluation of fused thio- and selenopyrans as new indolocarbazole analogues with aryl hydrocarbon receptor affinity. Bioorg Med Chem 2009, 17:1648-1653.
• [103]Sinha D, Tiwari AK, Singh S, Shukl G, Mishra P, Chandra H, Mishra AK: Synthesis, characterization and biological activity of Schiff base analogues of indole-3-carboxaldehyde. J Med Chem 2008, 43:160-165.
• [104]Bhattacharjee AK, Hartell MG, Nichols DA, Hicks RP, Stanton B, Hamont JE, Milhous WK: Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates. J Med Chem 2004, 39:59-67.
• [105]Prudhomme M: Rebeccamycin analogues as anti-cancer agents. J Med Chem 2003, 38:123-140.
• [106]He L, Chang H, Chou TC, Savaraj N, Cheng CC: Design of antineoplastic agents based on the ‘2-phenylnaphthalene-type’ structural pattern—synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. J Med Chem 2003, 38:101-107.